Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Malignant Renal Pelvis Neoplasm
Explore 12 assets in Malignant Renal Pelvis Neoplasm →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04963153CT.gov Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Renal Pelvis Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 (this asset) | National Cancer Institute (NCI) | P1 | CC · 43 |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | Fred Hutchinson Cancer Center | P2 | BB |
| Pembrolizumab | Fred Hutchinson Cancer Center | P2 | B |
| Atezolizumab | National Cancer Institute (NCI) | P2 | B |
| Apsolol | Emory University | P2 | CCC |
| Eribulin Monomethanesulfonate | National Cancer Institute (NCI) | P2 | CCC |
| Relatlimab | M.D. Anderson Cancer Center | P2 | CCC |
| Nivolumab | M.D. Anderson Cancer Center | P2 | CCC |
| Tocilizumab | M.D. Anderson Cancer Center | P2 | CCC |
+6 more in the Malignant Renal Pelvis Neoplasm cohort
Other indications for Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P2 | B · 60 |
| Bladder Transitional Cell Carcinoma | — | P2 | B · 58 |
| Hepatocellular Carcinoma | — | P2 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Fred Hutchinson Cancer CenterBB
- PembrolizumabFred Hutchinson Cancer CenterB
- AtezolizumabNational Cancer Institute (NCI)B
- ApsololEmory UniversityCCC
- Eribulin MonomethanesulfonateNational Cancer Institute (NCI)CCC
Citation
Floatz Terminal. Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 in Malignant Renal Pelvis Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pan-fgfr-tyrosine-kinase-inhibitor-jnj-42756493-malignant-renal-pelvis-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →